Similar articles

• Part II. Introduction to the beta-lactam antibiotics.

  Cooper TW, Gibbs WJ, Bronze MS, Greenfield RA. Cooper TW, et al. J Okla State Med Assoc. 2006 Oct;99(10):516-20. J Okla State Med Assoc. 2006. PMID: 17125105 Review. No abstract available.
• Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?

  You JH, Kei HW, Lau WC, Wong KY, Marasinghe T, Lee N, Ip M. You JH, et al. J Hosp Infect. 2008 Feb;68(2):181-3. doi: 10.1016/j.jhin.2007.11.014. Epub 2008 Jan 14. J Hosp Infect. 2008. PMID: 18194826 No abstract available.
• Beta-lactam antibiotics: newer formulations and newer agents.

  Martin SI, Kaye KM. Martin SI, et al. Infect Dis Clin North Am. 2004 Sep;18(3):603-19, ix. doi: 10.1016/j.idc.2004.04.006. Infect Dis Clin North Am. 2004. PMID: 15308278 Review.
• Parenteral carbapenems.

  Shah PM. Shah PM. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:175-80. doi: 10.1111/j.1469-0691.2007.01868.x. Clin Microbiol Infect. 2008. PMID: 18154543 Review.
• [Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe].

  Cavallo JD, Mérens A. Cavallo JD, et al. Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):435-8. doi: 10.1016/j.patbio.2008.07.028. Epub 2008 Nov 18. Pathol Biol (Paris). 2008. PMID: 19019568 French.